MA52662A - Conjugués d'il-2 - Google Patents
Conjugués d'il-2Info
- Publication number
- MA52662A MA52662A MA052662A MA52662A MA52662A MA 52662 A MA52662 A MA 52662A MA 052662 A MA052662 A MA 052662A MA 52662 A MA52662 A MA 52662A MA 52662 A MA52662 A MA 52662A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18164682 | 2018-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52662A true MA52662A (fr) | 2021-02-17 |
Family
ID=61832449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052662A MA52662A (fr) | 2018-03-28 | 2019-03-27 | Conjugués d'il-2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12565525B2 (fr) |
| EP (1) | EP3773680A1 (fr) |
| JP (2) | JP7490563B2 (fr) |
| KR (2) | KR20250130705A (fr) |
| CN (2) | CN119504973A (fr) |
| AU (2) | AU2019246389B2 (fr) |
| BR (1) | BR112020019639A2 (fr) |
| CA (1) | CA3093722A1 (fr) |
| IL (3) | IL277572B2 (fr) |
| MA (1) | MA52662A (fr) |
| MX (2) | MX2020009857A (fr) |
| SG (1) | SG11202007524QA (fr) |
| WO (1) | WO2019185705A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49767A (fr) | 2017-08-03 | 2021-05-26 | Synthorx Inc | Conjugués de cytokine pour le traitement de maladies auto-immunes |
| BR112020019639A2 (pt) | 2018-03-28 | 2021-01-05 | Ascendis Pharma Oncology Division A/S | Conjugados de il-2 |
| CN113260374A (zh) | 2018-11-08 | 2021-08-13 | 新索思股份有限公司 | 白介素10缀合物及其用途 |
| EP3906065B1 (fr) | 2019-01-04 | 2025-04-30 | Ascendis Pharma Oncology Division A/S | Agoniste de prr et son utilisation dans le traitement du cancer |
| JP2022516314A (ja) | 2019-01-04 | 2022-02-25 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | 自然免疫アゴニストのための持続性局所性薬物レベル |
| EP3906060A1 (fr) | 2019-01-04 | 2021-11-10 | Ascendis Pharma Oncology Division A/S | Conjugués d'agonistes du récepteur de reconnaissance de motif |
| CA3127689A1 (fr) | 2019-02-06 | 2020-08-13 | Synthorx, Inc. | Conjugues d'il-2 et methodes d'utilisation de ceux-ci |
| WO2020254607A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés anti-ctla4 à propriétés pd localisées |
| EP3986479A1 (fr) | 2019-06-21 | 2022-04-27 | Ascendis Pharma Oncology Division A/S | Conjugués anti-ctla4 |
| US12344648B2 (en) | 2019-08-23 | 2025-07-01 | Synthrox, Inc. | IL-15 conjugates and uses thereof |
| AU2020347154A1 (en) | 2019-09-10 | 2022-03-03 | Synthorx, Inc. | IL-2 conjugates and methods of use to treat autoimmune diseases |
| EP4072576A4 (fr) * | 2019-12-13 | 2024-01-03 | Synthekine, Inc. | Orthologues de l'il-2 et procédés d'utilisation |
| CN111018961B (zh) * | 2019-12-17 | 2022-03-18 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| IL297329A (en) | 2020-04-22 | 2022-12-01 | Merck Sharp & Dohme Llc | Dimeric interleukin-2 beta gamma receptor-biased human interleukin-2 conjugates conjugated to soluble non-peptide polymers. |
| IL298642A (en) | 2020-06-03 | 2023-01-01 | Ascendis Pharma Oncology Div A/S | il-2 sequences and uses thereof |
| TW202219060A (zh) | 2020-08-28 | 2022-05-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 醣基化il-2蛋白及其用途 |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| WO2023017191A1 (fr) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Combinaison d'agonistes de l'il-2/il-15rbetagamma avec des conjugués anticorps-médicament pour le traitement du cancer |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| AU2000202A (en) | 2000-10-31 | 2002-05-15 | Pr Pharmaceuticals Inc | Methods and compositions for enhanced delivery of bioactive molecules |
| EP1476180A4 (fr) | 2001-08-13 | 2005-04-20 | Univ Southern California | Mutants d'interleukine-2 a toxicite reduite |
| BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| CA2843439A1 (fr) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Medicaments pegyles reversibles |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| CA2539253A1 (fr) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Nouveaux derives de glp-1 |
| JP5744369B2 (ja) * | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体 |
| WO2005091956A2 (fr) | 2004-03-05 | 2005-10-06 | Chiron Corporation | Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients |
| JP4950022B2 (ja) * | 2004-03-23 | 2012-06-13 | コンプレックス バイオシステムズ ゲーエムベーハー | 自壊性リンカーを有する高分子プロドラッグ |
| MX2007007590A (es) | 2004-12-22 | 2007-12-10 | Ambrx Inc | Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos. |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
| HRP20110368T1 (hr) | 2007-06-21 | 2011-06-30 | Technische Universitt Mnchen | Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro |
| EP2175878A4 (fr) | 2007-07-11 | 2014-12-03 | Belrose Pharma Inc | Système d'administration de médicament polymérique contenant un groupement aromatique multi-substitué |
| CN101980725B (zh) | 2008-02-01 | 2013-06-12 | 阿森迪斯药物股份有限公司 | 包含可自裂解的连接体的前药 |
| DK2279007T3 (en) | 2008-04-29 | 2016-08-22 | Ascendis Pharma Growth Disorders Div As | Pegylated recombinant relations of human growth hormone |
| EP2288261A4 (fr) | 2008-05-23 | 2013-09-25 | Enzon Pharmaceuticals Inc | Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d oligonucléotides |
| AU2010206840B2 (en) | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| SI2393828T1 (sl) | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
| US8331611B2 (en) | 2009-07-13 | 2012-12-11 | Raytheon Company | Overlay information over video |
| US20110007134A1 (en) | 2009-07-13 | 2011-01-13 | Raytheon Company | Synchronizing video images and three dimensional visualization images |
| WO2011008613A1 (fr) | 2009-07-16 | 2011-01-20 | Skyhook Wireless, Inc. | Systemes et procedes pour utiliser un satellite hybride et un systeme de positionnement wlan |
| ES2833035T3 (es) | 2009-07-31 | 2021-06-14 | Ascendis Pharma As | Hidrogeles biodegradables insolubles en agua a base de polietilenglicol |
| EP2464654B1 (fr) | 2009-08-10 | 2014-10-08 | UCL Business PLC | Groupement protecteur thiol |
| CU23734A1 (es) | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| DK2512450T3 (en) * | 2009-12-15 | 2018-04-23 | Ascendis Pharma Endocrinology Div A/S | Dry growth hormone composition transiently bound to a polymer carrier |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| US9561285B2 (en) * | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| JP5977229B2 (ja) | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| DK2566334T3 (en) | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
| AU2011254564B2 (en) | 2010-05-21 | 2014-03-27 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| US8989456B2 (en) | 2010-06-30 | 2015-03-24 | Nec Solution Innovators, Ltd. | Attribute determining method, attribute determining apparatus, program, recording medium, and attribute determining system |
| HRP20210642T1 (hr) | 2010-11-12 | 2021-05-28 | Nektar Therapeutics | Konjugati il-2 ostatka i polimera |
| JP6093712B2 (ja) | 2010-12-22 | 2017-03-08 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン２のスーパーアゴニストおよびアンタゴニスト |
| US9266938B2 (en) | 2011-02-10 | 2016-02-23 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| WO2013024048A1 (fr) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Promédicaments liés à des excipients polymériques hyperbranchés |
| AU2012302778B2 (en) * | 2011-08-31 | 2016-11-24 | Mie University | Vaccine preparation for cancer treatment |
| WO2013036857A1 (fr) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Coupleurs au sulfone |
| WO2014028748A1 (fr) | 2012-08-15 | 2014-02-20 | Irm Llc | Anticorps d'interleukine 2 et complexes d'anticorps |
| SG11201501914XA (en) | 2012-10-11 | 2015-05-28 | Ascendis Pharma Ophthalmology Division As | Vegf neutralizing prodrugs for the treatment of ocular conditions |
| US9855340B2 (en) | 2012-10-11 | 2018-01-02 | Ascendis Pharma A/S | Hydrogel prodrugs |
| CN104955472A (zh) | 2012-10-17 | 2015-09-30 | 诺和诺德保健股份有限公司 | 用于生长激素递送的脂肪酸酰化的氨基酸 |
| WO2014100014A1 (fr) | 2012-12-17 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Super-complexes 2 avec anticorps pour une amélioration de la thérapie par il-2 |
| WO2015042707A1 (fr) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Protéines hybrides de l'interleukine-2 et leurs utilisations |
| US10010587B2 (en) * | 2014-02-21 | 2018-07-03 | Nektar Therapeutics | IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody |
| AU2015299055C1 (en) | 2014-08-06 | 2021-05-06 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| SG11201700629TA (en) | 2014-08-11 | 2017-02-27 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| US10799563B2 (en) * | 2014-11-18 | 2020-10-13 | Ascendis Pharma Endocrinology Division | Polymeric hGH prodrugs |
| CA3007976C (fr) * | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Promedicaments du cnp possedant de grands fragments a role de transporteur |
| SMT202400423T1 (it) | 2016-03-01 | 2024-11-15 | Ascendis Pharma Bone Diseases As | Profarmaci di pth |
| HUE070273T2 (hu) * | 2016-09-29 | 2025-05-28 | Ascendis Pharma Bone Diseases As | Szabályozott hatóanyag-leadású PTH vegyületek |
| CU24483B1 (es) | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| EP3600441A1 (fr) | 2017-03-22 | 2020-02-05 | Genentech, Inc. | Compositions de promédicament d'hydrogel d'acide hyaluronique réticulé et procédés |
| MA49767A (fr) | 2017-08-03 | 2021-05-26 | Synthorx Inc | Conjugués de cytokine pour le traitement de maladies auto-immunes |
| KR102771546B1 (ko) * | 2017-11-08 | 2025-02-21 | 야페이 상하이 바이오로지 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 | 생체분자의 컨쥬게이트 및 이의 용도 |
| KR102740971B1 (ko) | 2017-12-27 | 2024-12-11 | 쿄와 기린 가부시키가이샤 | Il-2 개변체 |
| BR112020019639A2 (pt) | 2018-03-28 | 2021-01-05 | Ascendis Pharma Oncology Division A/S | Conjugados de il-2 |
| US20210008168A1 (en) * | 2018-03-28 | 2021-01-14 | Ascendis Pharma A/S | Conjugates |
| JP7550745B2 (ja) | 2018-07-24 | 2024-09-13 | バイオエヌテック エスエー | Ｉｌ２アゴニスト |
| TWI791894B (zh) | 2018-09-21 | 2023-02-11 | 大陸商信達生物製藥（蘇州）有限公司 | 新型白介素２及其用途 |
| KR20220012256A (ko) | 2019-05-24 | 2022-02-03 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
| WO2020254607A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés anti-ctla4 à propriétés pd localisées |
| CN111018961B (zh) | 2019-12-17 | 2022-03-18 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| IL298642A (en) | 2020-06-03 | 2023-01-01 | Ascendis Pharma Oncology Div A/S | il-2 sequences and uses thereof |
| TW202219060A (zh) | 2020-08-28 | 2022-05-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 醣基化il-2蛋白及其用途 |
-
2019
- 2019-03-27 BR BR112020019639-8A patent/BR112020019639A2/pt unknown
- 2019-03-27 MA MA052662A patent/MA52662A/fr unknown
- 2019-03-27 KR KR1020257027619A patent/KR20250130705A/ko active Pending
- 2019-03-27 CN CN202411614476.4A patent/CN119504973A/zh active Pending
- 2019-03-27 IL IL277572A patent/IL277572B2/en unknown
- 2019-03-27 KR KR1020207031136A patent/KR20200139730A/ko active Pending
- 2019-03-27 IL IL308797A patent/IL308797B1/en unknown
- 2019-03-27 AU AU2019246389A patent/AU2019246389B2/en active Active
- 2019-03-27 CN CN201980022172.XA patent/CN111918665B/zh active Active
- 2019-03-27 JP JP2020552812A patent/JP7490563B2/ja active Active
- 2019-03-27 US US17/042,610 patent/US12565525B2/en active Active
- 2019-03-27 WO PCT/EP2019/057709 patent/WO2019185705A1/fr not_active Ceased
- 2019-03-27 IL IL324874A patent/IL324874A/en unknown
- 2019-03-27 EP EP19713040.4A patent/EP3773680A1/fr active Pending
- 2019-03-27 SG SG11202007524QA patent/SG11202007524QA/en unknown
- 2019-03-27 CA CA3093722A patent/CA3093722A1/fr active Pending
- 2019-03-27 MX MX2020009857A patent/MX2020009857A/es unknown
-
2020
- 2020-09-22 MX MX2025007999A patent/MX2025007999A/es unknown
-
2024
- 2024-02-22 JP JP2024025984A patent/JP2024073467A/ja active Pending
- 2024-11-05 AU AU2024259730A patent/AU2024259730A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020019639A2 (pt) | 2021-01-05 |
| IL277572A (en) | 2020-11-30 |
| JP2021519336A (ja) | 2021-08-10 |
| IL277572B1 (en) | 2024-01-01 |
| IL324874A (en) | 2026-01-01 |
| EP3773680A1 (fr) | 2021-02-17 |
| IL277572B2 (en) | 2024-05-01 |
| WO2019185705A1 (fr) | 2019-10-03 |
| CN111918665B (zh) | 2024-11-26 |
| AU2024259730A1 (en) | 2024-12-05 |
| MX2025007999A (es) | 2025-08-01 |
| KR20250130705A (ko) | 2025-09-02 |
| CN111918665A (zh) | 2020-11-10 |
| US20210024602A1 (en) | 2021-01-28 |
| CN119504973A (zh) | 2025-02-25 |
| MX2020009857A (es) | 2021-01-08 |
| KR20200139730A (ko) | 2020-12-14 |
| JP7490563B2 (ja) | 2024-05-27 |
| SG11202007524QA (en) | 2020-09-29 |
| US12565525B2 (en) | 2026-03-03 |
| AU2019246389A1 (en) | 2020-08-27 |
| RU2020135268A (ru) | 2022-04-28 |
| IL308797A (en) | 2024-01-01 |
| AU2019246389B2 (en) | 2024-08-22 |
| IL308797B1 (en) | 2026-01-01 |
| JP2024073467A (ja) | 2024-05-29 |
| CA3093722A1 (fr) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52662A (fr) | Conjugués d'il-2 | |
| IL286291A (en) | Compounds and conjugates thereof | |
| EP3735685A4 (fr) | Panneau d'affichage | |
| EP3807644A4 (fr) | Conjugués anticorps-oligonucléotide | |
| DK3794042T3 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| EP3750149C0 (fr) | Panneau d'affichage | |
| EP3793613C0 (fr) | Immunoconjugués | |
| EP3798719A4 (fr) | Panneau d'affichage | |
| IL291486A (en) | Therapeutic conjugates | |
| IL284007A (en) | Rifamycin analogs and antibody-drug conjugates thereof | |
| EP3532240A4 (fr) | Base d'outillage | |
| IL292766A (en) | Antibody-drug conjugates targeting claudin 18.2 | |
| EP4030778A4 (fr) | Casque d'écoute | |
| EP3723787A4 (fr) | Récepteurs de l'interleukine darique | |
| EP3790683A4 (fr) | Ensemble d'entraînement | |
| EP3762456A4 (fr) | Composition de dispersant d'asphaltène | |
| EP3864058A4 (fr) | Composition photodurcissable | |
| EP3773574A4 (fr) | Formulations d'amlodipine | |
| EP3761922C0 (fr) | Support d'épaule orthétique | |
| IL279855A (en) | Improvements in immunogenic conjugates | |
| DK3911298T3 (da) | Formuleringer | |
| EP3851070A4 (fr) | Structure d'implant | |
| EP3792601A4 (fr) | Détecteur d'angle | |
| EP3742509A4 (fr) | Panneau d'affichage | |
| EP3585438A4 (fr) | Conjugués d'androstènedione chimioluminescents |